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The involvement of extracellular nucleotides and adenosine in an array of cell-specific responses has long been known and appreciated, but the
integrative view of purinergic signalling as a multistep coordinated cascade has emerged recently. Current models of nucleotide turnover include:
(i) transient release of nanomolar concentrations of ATP and ADP; (ii) triggering of signalling events via a series of ligand-gated (P2X) and
metabotropic (P2Y) receptors; (iii) nucleotide breakdown by membrane-bound and soluble nucleotidases, including the enzymes of ecto-nucleoside
triphosphate diphosphohydrolase (E-NTPDase) family, ecto-nucleotide pyrophosphatase/phosphodiesterase (E-NPP) family, ecto-5'-nucleotidase/
CD73, and alkaline phosphatases; (iv) interaction of the resulting adenosine with own nucleoside-selective receptors; and finally, (v) extracellular
adenosine inactivation via adenosine deaminase and purine nucleoside phosphorylase reactions and/or nucleoside uptake by the cells. In contrast to
traditional paradigms that focus on purine-inactivatingmechanisms, it has now become clear that “classical” intracellular ATP-regenerating enzymes,
adenylate kinase, nucleoside diphosphate (NDP) kinase and ATP synthase can also be co-expressed on the cell surface. Furthermore, data on the
ability of various cells to retain micromolar ATP levels in their pericellular space, as well as to release other related compounds (adenosine, UTP,
dinucleotide polyphosphates and nucleotide sugars) gain another important insight into our understanding of mechanisms regulating a signalling
cascade. This review summarizes recent advances in this rapidly evolving field, with particular emphasis on the nucleotide-releasing and purine-
converting pathways in the vasculature.
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ATP and other nucleotides and nucleosides are found in all
animal organ systems where they produce effects both by in-
tracellular and extracellular mechanisms. Intracellular ATP is
primarily utilised to drive energy-requiring processes such as
active transport, cell motility and biosynthesis, whereas extra-
cellular ATP is considered a powerful signalling molecule. The
concept of purinergic neurotransmission was first proposed by
G. Burnstock over three decades ago [1]. Since that time, clear
signalling roles for ATP and other nucleotides (ADP, UTP,
UDP) have been established in several tissues, including potent⁎ Tel.: +358 2 5340616; fax: +358 2 3337000.
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doi:10.1016/j.bbamcr.2008.01.024neurotransmission in the central nervous system, non-adrener-
gic, non-cholinergic smooth muscle contractility and neuron–
glia interactions [2,3], inotropic, chronotropic, and arrhythmo-
genic effects in the myocardium [4]; gastrointestinal and liver
function [5], regulation of epithelial cell responses [6,7]; blood
flow distribution and oxygen delivery [8,9]; immune responses
and control of leukocyte trafficking between the blood and tis-
sues [10,11], and activation and aggregation of platelets at
sites of vascular injury [12,13]. In addition to acute signalling
events, there is increasing awareness that purines and pyrimi-
dines also have potent long-term (trophic) roles in cell proli-
feration and growth [14], induction of apoptosis and anticancer
activity [10,15], atherosclerotic plaque formation [16], wound
healing and bone formation and resorption [17].
All these effects are mediated via a series of nucleotide-selective
receptors and, on the basis of pharmacological, functional and
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been described (Fig. 1). The P2X receptors are ligand-gated
channels that gate extracellular cations in response to ATP and
comprise seven receptor subtypes (P2X1 through P2X7) [2,18]. The
P2Y receptors are G-protein-coupled receptors that are categorized
into a subfamily of receptors that predominantly couple to Gq
(P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11) and therefore activate
phospholipase C-β, and into a subfamily of Gi-coupled receptors
(P2Y11, P2Y12, P2Y13, and P2Y14) that inhibit adenylyl cyclase and
regulate ion channels [19]. Note, P2Y11 receptor is dually coupled
to phospholipase C and adenylyl cyclase stimulation. Pharma-
cologically, P2Y receptors can be subdivided into the adenine-
nucleotide-preferring receptors mainly responding to ATP and
ADP (human and rodent P2Y1, P2Y12, and P2Y13 and human
P2Y11), the uracil-nucleotide-preferring receptors (human P2Y4
and P2Y6) responding to either UTP or UDP, receptors of mixed
selectivity (human and rodent P2Y2 and rodent P2Y4), as well as
nucleotide-sugar-preferring human P2Y14 receptor responding to
UDP-glucose and UDP-galactose [19,20].
Subsequent to the signal transduction, extracellular nucleo-
tides need to be rapidly inactivated to adenosine (Fig. 2). General
schemes of nucleotide hydrolysis have included a role for (i) ecto-
nucleoside triphosphate diphosphohydrolase (E-NTPDase) fa-
mily [21,22], (ii) ecto-nucleotide pyrophosphatase/phosphodies-
terase (E-NPP) family [23,24], (iii) ecto-5'-nucleotidase [25–27],
and (iv) alkaline phosphatases (AP) [28]. Strikingly, along with
the common view of extracellular ATP as a ligand for P2 re-
ceptors, substrate for ecto-nucleotidases and source of adeno-
sine, this nucleotide was shown to concurrently serve as a
phosphoryl donor for counteracting ecto-adenylate kinase (AK)
and nucleoside diphosphate (NDP) kinase reactions [29,30]. The
resulting adenosine in turn has a non-redundant counteracting
role in the attenuation of inflammation and tissue damage and
mediates diverse cardioprotective, neuroprotective, vasodilata-
tory and angiogenic responses [10,31–33]. These effects are
mediated throughG-protein-coupled adenosine receptors (Fig. 1),Fig. 1. Purinergic signalling pathways. Nucleotides mediate signalling effects through
classified by their affinities towards ATP, ADP and other putative nucleotide and nucl
four own G-protein-coupled nucleoside-selective receptors.that function either by activating (A2A and A2B) or inhibiting
(A1 and A3) adenylate cyclase and are classified according to
their affinities for adenosine [2,31,33]. Extracellular adenosine is
then transported into the cell either via equilibrative nucleoside
transporters, which transport nucleosides, nucleobases and or-
ganic cations as facilitated diffusion-limited channels or through
the concentrative nucleoside transporters which are selective for
sodium and can also use lithium and proton gradients to drive
concentrative fluxes of purine and pyrimidine nucleosides
[34,35]. Alternatively, adenosine can be directly inactivated on
the cell surface via inosine to hypoxanthine through sequential
ecto-adenosine deaminase (ADA) and purine nucleoside phos-
phorylase (PNP) activities [31,36] (Fig. 2).
Collectively, extracellular purine turnover includes the release of
ATP and other agonists, triggering of signalling events and
subsequent inactivation. Despite the significant progress in our
understanding of the purinergic machinery as a multistep cascade,
current knowledge on the whole sequence of “release-signalling-
inactivation” is rather limited. This review summarizes recent
advances and some controversies in this rapidly evolving field, with
particular emphasis on the nucleotide-releasing and inactivating
pathways. Since our laboratory has had a long-lasting interest in
various aspects of intravascular nucleotide turnover, special
attention is also given to the role of nucleotides and adenosine
in the immunomodulatory and thromboregulatory responses.
2. Release of ATP and other agonists into the extracellular
milieu
2.1. Extracellular ATP and ADP release
The release of endogenous nucleotides represents a critical
component for initiating a signalling cascade. Massive leakage of
nucleotides might occur upon cell lysis, however this nonspecific
mechanism is restricted by organ injury, traumatic shock or
certain inflammatory conditions [10]. Non-lytic mechanisms ofa series of ionotropic P2X receptors and metabotropic P2Y receptors, which are
eotide-sugar agonists. The generated nucleotide-derived adenosine in turn acts at
Fig. 2. Major purine-inactivating activities on the cell surface. The nucleotide-hydrolysing pathway comprises at least three ectoenzymes, E-NPP, E-NTPDase and
ecto-5'-nucleotidase. The resulting adenosine (Ado) can be further deaminated via inosine (Ino) into hypoxanthine (Hyp) through sequential ADA and PNP reactions.
Note, this cartoon particularly highlights the inactivating mechanisms for adenine nucleotides and adenosine. However, other nucleotides and related compounds also
serve as preferred substrates for these ectoenzymes.
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nucleotide appearance in the extracellular milieu. Various ex-
citatory/secretory tissues such as nerve terminals and chromaffin
cells [3,37], pancreatic acinar cells [38] and circulating platelets
[12,13] storeATP andADP, togetherwith other neurotransmitters
and extracellular mediators, in specialized granules (called syn-
aptic vesicles, chromaffin granules or dense core granules) and
regulate the release of nucleotide-containing vesicles in a Ca2+-
dependent manner via regulated exocytosis. Moreover, nucleo-
tide release occurs from various non-excitatory tissues, including
the epithelial [6,39–41] and endothelial cells [42–44], astrocytes
and other glial cells [3,40], fibroblasts [45], hepatocytes [5,46],
bone cells, joints and keratinocytes [3,17,47], cardiomyocytes
[4], erythrocytes [9], neutrophils [48], monocytes/macrophages
[49] and other hematopoietic cells [10]. These cells have been
shown to release ATP transiently under various mechanical and
other stimuli, such as shear stress, hypotonic swelling, hypoxia,
stretching, hydrostatic pressure, as well as in response to brady-
kinine, serotonin and other Ca2+-mobilizing pharmacological
agonists. Moreover, the cells release low nanomolar concentra-
tions of ATP at certain basal rates [19,40,41] and distinctive
mechanisms could underlie constitutive versus stress-stimulated
nucleotide release. The diversity of conditions in which the cells
release ATP and/or ADP suggests the implication of multiple
nucleotide-releasing pathways. The proposed cellular mechan-
isms might include (1) electrodiffusional movement through
membrane ion channels, including connexin hemichannels,
stretch- and voltage-activated channels; (2) facilitated diffusion
by nucleotide-specific ATP-binding cassette (ABC) transporters,
such as the cystic fibrosis transmembrane conductance regulator
(CFTR), the multidrug resistance proteins, and the multiple
organic anion transporters; and (3) cargo-vesicle trafficking and
exocytotic granule secretion [6,20] (Fig. 3).2.2. AMP and adenosine appearance in the extracellular milieu
Stimulation of human neutrophils with phorbol myristate
acetate (PMA) or N-formyl-Met-Leu-Phe (fMLP) was accom-
panied by accumulation of micromolar AMP concentrations;
and this extracellular neutrophil-derived secretagogue was
shown to elicit chloride secretion from epithelial cells [50,51],
promote endothelial barrier function [48,52] and guide neu-
trophil chemotaxis [53], most likely via CD73-mediated con-
version to adenosine and subsequent activation of adenosine
receptors. Given the high numbers of neutrophils in these assays
(4–10×107 cells/mL) and relatively low ratios of ecto-5'-
nucleotidase-to-NTPDase activities in the neutrophils, it remains
unclear whether AMP is directly liberated from the stimulated
neutrophils or accumulated as an intermediate metabolite from
the released precursor nucleotides ATP and ADP.
Another important molecule, adenosine, could also appear in
the extracellular milieu either via direct release of endogenous
nucleoside or as a result of ATP/ADP breakdown via sequential
ecto-nucleotidase reactions. Measurements of extracellular ade-
nosine levels (by using enzyme-coupled chemiluminescent or
electrochemical methods) demonstrated direct hypoxia-induced
releases of micromolar concentrations of this nucleoside from
the rat hippocampal slices and cultured rat cortical astrocytes
[54,55]. Amperometric measurement of extracellular adenosine
in murine thalamic slices using needle-shaped biosensors also
detected that extracellular adenosine can be increased up to
micromolar levels in response to high-frequency stimulation,
thereby controlling deep brain stimulation and tremor activity
via activation of A1 receptors [56]. However, this nucleoside
accumulation was shown to primarily occur due to the transient
release of ATP from the activated cortex with subsequent ecto-
enzymatic nucleotide breakdown to adenosine.
Fig. 3. Nucleotide-releasing pathways. Along with massive nucleotide leakage upon cell damage, nucleotides can appear in the external milieu via various non-lytic
pathways, including electrodiffusional movement through ATP release channels, facilitated diffusion by nucleotide-specific transporters and vesicular exocytosis.
Furthermore, preferential segregation of micromolar concentrations of “ATP halo” in the pericellular space and its exchange with bulk extracellular ATP pool via
certain dissociation–association mechanisms has been proposed recently.
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chromatographic (HPLC) analysis of fluorescent 1,N 6-ethenoa-
denine derivatives, it has been shown that ATP release and
metabolism constitutes a primary source for the accumulation of
relatively high (~10−7 mol/L) concentrations of adenosine,
AMP and ADP within the bathing liquid covering cultures of
human airway epithelial cells [57,58]. The latter studies addi-
tionally emphasized that continuous generation of adenosine
provides sustained basal activity to the A2b receptor and controls
CFTR function and airway surface liquid homeostasis. Data on
significantly decreased tissue adenosine levels and the impaired
adenosine receptor-mediated signalling in carotid arteries
[59,60] and myocardium [61] of ecto-5'-nucleotidase/CD73-
deficient mice reasonably suggest that in the case of cardiovas-
cular system the nucleotide-inactivating chain also represents
the major route for generation of extracellular adenosine.
2.3. Release of UTP and nucleotide sugars
Identification of UTP/UDP-selective P2Y4 and P2Y6 re-
ceptors reasonably suggests that uracil nucleotides can also be
released as extracellular signalling molecules. Indeed, the ability
of various cell types to release low nanomolar UTP concentra-
tions has been directly confirmed by developing a highly se-
lective UDP-glucose pyrophosphorylase-coupled reaction with
subsequent measurement of the UTP-dependent conversion of
[14C]glucose-1-phosphate to UDP-[14C]glucose [20,62,63].
Studies with murine airway epithelial cells transfected with the
P2Y4 receptor also demonstrated significant UTP release from
the mechanically stimulated cells which, in turn, contributes to
the generation of Ca2+ waves and coordination of the integrated
epithelial stress response [39]. Induction of brain injury and
neuronal death in rats induced by administration of an excitatory
kainic acid caused marked releases of micromolar concentra-
tions of extracellular UTP both in vivo and in vitro, followed by
its immediate hydrolysis to UDP and subsequent activation of
P2Y6-receptor-mediated microglial phagocytosis [64]. Like-
wise, recent studies with humans revealed significant increasein circulating UTP levels during acute myocardial infarction
(which most likely occurs due to the transient nucleotide release
by cardiomyocytes), and further demonstrated the important role
for extracellular UTP and UDP as novel inotropic factors in-
volved in the development of cardiac disease [65].
By developing a sensitive HPLC-based radiometric assay for
detection of UDP-glucose mass, it has been demonstrated that
mechanically stimulated 1321N1 human astrocytoma cells, pri-
mary airway epithelia and other cell types also release nano-
molar concentrations (~5–10 nM) of UDP-glucose [58,66].
Unlike transient releases of nucleotide agonists, UDP-glucose
is released at a considerably slower rate, but its extracellular
level remains stable for at least 3 h. The physiological signi-
ficance of the regulated release of cellular UDP-glucose (and
probably also of UDP-galactose) is heightened by observation
of a novel P2Y14 receptor subtype (previously known as an
orphanG-protein-coupled receptorKIA0001 orGPR105), which
is expressed in placenta, adipose tissue, stomach, intestine and
other tissues and specifically responds to UDP-glucose and re-
lated sugar-nucleotides [67].
2.4. Release of dinucleoside polyphosphates
Diadenosine polyphosphates (ApnA; n=2–6) are a group of
dinucleosides consisting of two adenosine molecules bridged by a
variable number of phosphates, which have a relatively long half-
life and, after degradation, may serve as a potential source of
extracellular ATP and other purines. ApnA are produced and
released from adrenal glands, platelets and chromaffin cells (where
they are co-stored in granules with ATP and catecholamines), and
substantial amounts have been also found in the human
myocardium [4,68,69]. ApnA serve as important neurotransmitter
molecules in the nervous system [70] and in addition, stimulate
different responses in the cardiovascular system, controlling
vascular tone and preventing platelet aggregation [68,71]. Inter-
estingly, certain amounts of other dinucleoside phosphates,
adenosine (5') oligophospho-(5') guanosines (ApnG; n=3–6)
and oligophospho-(5') guanosines (GpnG; n=3–6), can also be
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contributing to the regulation of blood flow and vascular growth
under physiological and pathological conditions [72].Moreover,
along with ATP and UTP, mechanically stimulated endothelial
cells release nanomolar concentrations of uridine adenosine
tetraphosphate (Up4A), with the latter dinucleotide being
involved in endothelial-derived vasoconstriction [73].
Some dinucleoside polyphosphates have the capacity to po-
tentiate signalling effects via P2 receptors (primarily, via P2X1,
P2X3 and P2Y1 subtypes), although the existence of specific
dinucleotide receptors has also been proposed [70,71]. How-
ever, the specificity of dinucleotide receptors is still poorly
understood, primarily due to the complexity of purinergic sig-
nalling system. For example, the released ApnA can be hydro-
lysed by the enzymes of NPP family [74] so that the response of
the cell should be the integral of various effects of dinucleotides
and their biologically active metabolites, ATP, ADP or adeno-
sine. Furthermore, the recent identification of membrane-bound
and soluble forms of AK [75–77] and powerful inhibition of
this catalytic reaction by Ap5A [78] could provide another
reasonable explanation of the agonistic effects of this bisub-
strate analogue. Indeed, the ability of Ap5A to stimulate the
endocytosis of high-density lipoproteins in human hepatocytes
was shown to be mediated via inhibition of ecto-AK mediated
conversion of endogenous ADP, with subsequent stimulation of
P2Y13-receptors [46]. Likewise, data on the ability of Ap4A to
inhibit the pattern of extracellular ATP catabolism [79], should
also be taken into consideration during evaluation of agonistic
potency for this dinucleotide.
3. Detection of ATP in the vicinity of the cell using innovative
ATP-sensing assays
“Classical” studies on ATP release generally involve either
agitation of cell suspensions/monolayers followed by removal of
bathing medium and bioluminescent detection of ATP content,
or direct addition of luciferase/luciferin reagent to the cells for
sensing ATP in real time [6]. Although highly specific and
sensitive, such an approach suffers from a limited capacity, firstly
because of the rapid ATP metabolism by surface-associated
nucleotidases and, secondly, by the compromising effects of
certain pharmacological reagents on luciferase activity and light
output. Moreover, activation of most P2 receptors usually occurs
at nucleotide concentrations within the range of 10−6–10−4 M
[10], that significantly exceeds the nanomolar ATP levels re-
ported for extracellular fluids. Recent innovative nucleotide-
sensing assays provide independent lines of evidence that most
of the released ATP is retained in the pericellular space without
significant convection into the bulkmilieu (Fig. 3) and these cell-
surrounding ATP concentrations are sufficient for triggering
purinergic responses.
3.1. Microscopic visualisation of ATP pools by using luciferin,
quinacrine and other appropriate ATP sensors
By using atomic force microscopy in combination with a
myosin ATPase-coated sensor tip (cantilever), accumulation ofmicromolar ATP on surface of CFTR-transfected airway epithe-
lial cells has been shown [80]. Fluorescencemicroscopic analysis
of rat pancreatic acini loaded with the ATP sensor luciferin also
revealed local release of 4–9 µM ATP from the cells under
conditions of cholinergic stimulation [38]. Yet another fluores-
cent microscopic technique for visualising ATP release in real
time has been developed recently based on conversion of nico-
tinamide adenine dinucleotide phosphate, NADP+, to its reduced
form NADPH. Significant accumulation of micromolar concen-
trations of ATP has been detected with this approach at the
leading edge of human neutrophils in response to chemotactic
receptor stimulation with the chemoattractant fMLP [53,81], as
well as in the immediate vicinity of Jurkat T cells under hyper-
osmotic conditions or stimulationwith anti-CD3/CD28 antibodies
and phytohemagglutinin [81]. Perfusion of murine thalamic slices
with a solution containing luciferase and D-luciferin and si-
multaneous microscopic bioluminescent imaging of the emitted
photons also revealed transient release of micromolar ATP con-
centrations from the exposed cortex in response to high-frequency
electric stimulation [56]. While these techniques allow discerning
of micromolar ATP in the microenvironment surrounding living
cells, the relatively low sensitivities of semi-quantitative micro-
scopic analyses limit their application for routine measurements.
Cellular ATP can also be visualised by using the fluorescent
dye quinacrine, which belongs to the quinoline–acridine class,
binds to nucleic acids and is considered as the preferred avail-
able marker for detecting releasable ATP stores. Labelling of
rabbit ciliary epithelial cells [82], human umbilical vein endo-
thelial cells (HUVEC) [42], rat pancreatic acini [38], human
leukemic cell lines [83] and human airway epithelial cells [58]
with quinacrine revealed the accumulation of this acidotropic
dye within cytoplasmic granules beneath the plasma membrane
and further demonstrated marked decreases in its fluorescence
intensities under various stimuli (hypotonic stress, shear stress,
cholinergic stimulation, and ionomycin treatment).
3.2. Indirect quantification of pericellular ATP by using
biosensor-based approaches
Upon stimulation of a single pancreatic β-cell with glucose
or sulfonylurea glibenclamide, local ATP concentrations of over
25 µM were recorded using the patch-clamp technique with a
“biosensor” PC12 cell expressing P2X2 receptors [84]. How-
ever, correct interpretation of biosensor cell-based data is ham-
pered by receptor inactivation/desensitization or potential self-
activation of P2X receptors during ATP release from the sensor
cell [85] and, in addition, this sophisticated technique requires
three-dimensionally fine-controlled micromanipulators to bring
the sensor into the close proximity of the target cell. Yet another
electrochemical approach for in vivo sensing of ATP release
from the tissues has been developed recently by using micro-
electrode sensors coated with an ultrathin biolayer containing
glycerol kinase and glycerol-3-phosphate oxidase [86]. By in-
serting these biosensors into the Xenopus embryos, transient
releases of low micromolar ATP concentrations were recorded
from spinal cord during locomotor activity [86] and from the
anterior neural plate during eye-field development [87].
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reaction ATP+AMP↔2ADP, cell surface-associated AK was
exploited as an intrinsic probe for sensing pericellular ATP.
Thin-layer chromatography (TLC) autoradiographic analysis
revealed the ability of human lymphocytes, but not vascular
endothelial cells, of slightly converting [3H]AMP into high-
energy 3H-phosphoryls even without exogenous γ-phosphate-
donating ATP [30,88]. Subsequent kinetic studies confirmed that
various lymphoid cells constitutively retain micromolar con-
centrations of pericellular ATP, which can be quantified by the
extent of its ectoenzymatic transphosphorylation with exogen-
ous 3H/32P-labelled AMP [83]. This work additionally empha-
sized that cell-surrounding ATP might provide an important
signalling loop sufficient for self-activation of lymphocytes and
also for triggering purinergic responses in a paracrine fashion.
Note, due to the prolonged dynamics of transphosphorylation of
tracer AMP with endogenous ATP, this enzyme-coupled tech-
nique is not appropriate for detecting transient ATP fluxes.
3.3. Bioluminescent ATP-sensing assays with cell
surface-targeted luciferase
Another approach for detecting ATP release into localized
membrane microenvironments includes selective targeting of
luciferase to the cell surface. By using biotinylated cell surface-
immobilized firefly luciferase, dynamic and local thrombin-
mediated ATP efflux was monitored in the vicinity of human
pulmonary artery endothelial cells [89]. The experiments with
membrane-attached protein-A luciferase also revealed transient
release of 15–20 µM ATP from thrombin-activated platelets
[90], and further demonstrated that micromolar ATP concentra-
tions are transiently segregated in the vicinity of human astro-
cytoma cells [91] and at the apical membrane surfaces of
primary airway epithelia [41] upon cells challenging with Ca2+-
mobilizing agonists or hypotonic stress, respectively. Transfec-
tion of recombinant plasma membrane-targeted luciferase into
HEK293 cells stably transfected with the human or rat P2X7
receptor also revealed transient and local release of 100–
200 µM ATP in response to membrane stretching or during
P2X7 activation by a potent agonist benzoyl-ATP (BzATP) [92].
A limitation of these assays is the need for specially designed
surface antigens or cell lines appropriate for luciferase targeting.
Moreover, by measuring the relative increases in light output
or second messenger production, most of the above techniques
can detect only transient ATP fluxes under certain stimulated
conditions.
4. Nucleotide breakdown to adenosine via ecto-nucleotidase
reactions
4.1. Ecto-nucleoside triphosphate diphosphohydrolase
(E-NTDPase) family
The presence of specific nucleotide-hydrolysing activities at
the surface of many cell types had been recognized for a long
time, and information about these enzymes may be found in the
early literature under different names, including ecto-ATPase,ATP-diphosphohydrolase, apyrase, ATPDase, nucleoside dipho-
sphatase, etc. (for review see [37,93,94]). As a common feature,
these ectoenzymes are capable of hydrolysing nucleoside tri-
and/or diphosphates, but not monophosphates, require milli-
molar concentrations of Ca2+ and Mg2+ for maximal activity,
and remain insensitive to specific inhibitors of P-type, V-type,
and F-type ATPases. While the mechanism of sequential ATP
hydrolysis via ADP into AMP was initially thought to be me-
diated via two separate ATPase and ADPase activities [95,96],
more recent studies suggested that a single enzyme ATP-dipho-
sphohydrolase can dephosphorylate both ATP and ADP as
substrates [37,97]. Later, given the broad substrate specificity of
ecto-ATPase/ATPDase towards different purine and pyrimidine
nucleoside tri- and diphosphates, a more accurate termNTPDase
has been introduced for this ectoenzyme [98,99]. According to
the current nomenclature, all NTPDase family members should
be termed as NTPDase proteins and classified in order of dis-
covery and classification [22]. Namely, eight different ENTPD
genes encodemembers of the NTPDase protein family, with four
of the NTPDases (NTPDase1, 2, 3, and 8) being expressed as
cell surface-located enzymes. NTPDases 5 and 6 exhibit intra-
cellular localization and undergo secretion after heterologous
expression, while NTPDases 4 and 7 are entirely intracellularly
located, facing the lumen of cytoplasmic organelles.
The molecular identity of the first member of the E-NTPDase
family (NTPDase1) was unravelled over one decade ago. The
prototypic member of the enzyme had been cloned, sequenced
and identified as a cell activation antigen CD39, a putative B-cell
activation marker [100]. Subsequent experiments with purified
and cloned soluble ATP-diphosphohydrolase (apyrase) from
potato tubers [101] and from different mammalian tissues [102]
confirmed the significant homology of this enzyme to human
CD39. Data on the close correlation between CD39 expression
level and nucleotide-hydrolysing activity in lymphocytes and
CD39-transfected COS-7 cells further strengthened the hypoth-
esis that NTPDase1 is primarily attributed to the surface antigen
CD39 [102,103]. Further studies revealed the abundant expres-
sion of NTPDase1/CD39 on vascular endothelial and smooth
muscle cells [12,104,105], exocrine pancreas [106], dendritic
cells [107], lymphocytes [108] and in a variety of other cells
[22,109].
NTPDase2 is particularly associated with the adventitial
surfaces of the muscularised vessels [105,110], cultured astro-
cytes, non-myelating Schwann cells and other glial cells of the
central and peripheral nervous system [22,111]. Recent immu-
nohistochemical studies with adult and developing murine brain
revealed that NTPDase2, together with alkaline phosphatase,
plays an important role in purinergic control of embryonic,
postnatal and adult neurogenesis [111]. The experiments with
Xenopus embryos also demonstrated the abundant expression
of NTPDase2 in the mesodermal and endodermal layers and
further emphasized the key regulatory role for this nucleotidase
in the triggering of purinergic signalling and initiation of eye
development [87]. The expression of NTPDase3 is mainly
associated with axon-like neuronal structures in the brain, where
it may act as a pre-synaptic regulator of extracellular ATP levels
and coordinates multiple homeostatic systems, including
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characterisation of the last mammalian membrane-associated
NTPDase, named NTPDase8, revealed its predominant expres-
sion in the liver, with lower enzyme levels being detected in
jejunum and kidney [113]. Abundant expression of NTPDase8
in bile canaliculi and large blood vessels of liver suggests the
involvement of this ecto-nucleotidase in the regulation of bile
secretion and/or nucleoside salvage [114].
All cell-surface members of NTPDase family are highly gly-
cosylated proteins with molecular masses ~70–80 kDa, which
show close immunological cross-reactivity [21] and may exist
either in monomeric or in higher homooligomeric (dimeric to
tetrameric) states [115]. These enzymes contain two predicted
transmembrane domains at the N- and C-terminus with a large
extracellular loop containing a more central hydrophobic region
with five highly conserved sequence domains known as “apyrase
conserved regions” (ACR), with two of them (ACR1 and ACR4)
sharing common sequence homology with members of the actin/
HSP70/sugar kinase superfamily [22,116]. The NTPDases can
hydrolyse a variety of nucleoside di- and triphosphates, although
preferences vary considerably among individual enzymes. In
particular, ATP:ADP hydrolysis ratios for NTPDases 1, 2, 3 and 8
are of ~1–1.5:1, 10–40:1, 3–4:1 and 2:1, respectively [21,117].
Notwithstanding, due to the ability of NTPDases to sequentially
dephosphorylate ATP via ADP to AMP (with concomitant
cleavage of two phosphates), measurement of catalytic activity
using conventional Pi-liberated photometric assays can lead to
overestimation of actual ATP-hydrolysing activity. Indeed, more
reliable radio-TLC analyses of the rates of tracer ATP and ADP
conversions into their corresponding dephosphorylated metabo-
lites by human endothelial cells [76,118], lymphocytes [30] and
rat pancreatic juice [119] revealed that the ADP-hydrolysing
capacity of NTPDase1/CD39 may even exceed ATPase activity
by up to ~1.5–2.0-times. NTPDases may also have other func-
tions distinct from their catalytic properties alone, particularly via
intracellular interactions with a membrane scaffolding protein
RanBPM and subsequent direct modulation of ERK/Ras sig-
nalling pathways [22,120].
In terms of the vascular system, endothelial E-NTPDase1/
CD39 has been implicated in playing critical role through the
termination of prothrombotic and proinflammatory effects of
circulating ATP and ADP thus keeping the hemostatic process
tightly regulated to prevent excessive clot formation and vessel
occlusion [12,22,96]. This ectoenzyme is expressed by endo-
thelium and endocardium at the luminal surface of blood vessels
and efficiently inhibits and reverses platelet aggregation in the
presence of ATP and/or ADP [97,110]. In contrast to NTPDase1,
vascular NTPDase2 is mainly expressed by microvascular peri-
cytes and adventitial cells in muscularised vessels, where it
promotes platelet aggregation in the presence of ATP and further
facilitates aggregation in the presence of ADP [110]. Among the
circulating blood cells, the NTPDase1/CD39 has been identified
as major nucleotide-inactivating enzyme on neutrophils, mono-
cytes and certain T- and B-cell subsets, but not on platelets and
red blood cells [121,122]. Strikingly, recent data have shown
that constitutive expression of CD39 by a population of murine
CD4+/CD25+/Foxp3+ T regulatory (Treg) cells can increasetheir suppressive activity via dual mechanism, including sca-
venging of proinflammatory ATP [123] and simultaneous ge-
neration (in concert with CD73) of the immunosuppressive
adenosine with subsequent activation of A2A adenosine re-
ceptors [108]. On human Treg cells, the expression of CD39 is
restricted only to a specific subset of effector/memory-like cells
and its level can be significantly decreased in patients with the
remitting/relapsing form of multiple sclerosis (which are cha-
racterised by a reduced suppressive capacity of their Treg cells)
[123]. Probably, in humans the lymphoid NTPDase1/CD39 is
also important for the removal of ATP and coordinate regulation
of immune responses.
Data from mutant mice deficient in NTPDase1/CD39 or over-
expressing human CD39 further confirmed an important role for
this ectoenzyme in the control of hemostasis, platelet reactivity,
thrombotic reactions and vascular growth in vivo and further
support its therapeutic potential in clinical vascular diseases and
during transplantation [104,105,124,125]. Furthermore, studies
with CD39-null mice demonstrated an important role of CD39 in
preventing exacerbated skin inflammation triggered by irritant
chemicals [107], activation of integrin-associated signalling
pathways and abrogation of tumor angiogenesis and metastasis
[126], maintenance of pulmonary integrity during acute lung
injury [127] and in renal [128] and myocardial [129] protections
from ischemia–reperfusion injury. Interestingly, CD39-deficient
mice showed reduced T cell-dependent immune responses to
antigens [107] and more recent studies further demonstrated that
Treg cells from these mice display impaired suppressive pro-
perties in vitro and fail to block allograft rejection in vivo [108].
4.2. Ecto-nucleotide pyrophosphatase/phosphodiesterase
(E-NPP) family
The E-NPP family consists of seven structurally related
ectoenzymes (NPP1 through NPP7) that are numbered accord-
ing to their order of discovery. Members of this multigene
family possess surprisingly broad substrate specificity capable
of hydrolysing pyrophosphate and phosphodiester bonds in (di)
nucleotides, nucleic acids, nucleotide sugars, as well as in
choline phosphate esters and lysophospholipids [74]. Only the
first three members of this family, NPP1 (previous name plasma
cell differentiation antigen-1, PC-1), NPP2 (autotaxin, phos-
phodiesterase 1α) and NPP3 (gp130RB13-6, B10, phosphodies-
terase 1β), are capable of hydrolysing various nucleotides and
are therefore relevant in the context of the purinergic signalling
cascade [23]. In addition, NPP1–3 hydrolyse Ap3A, Ap4A and
Ap5A at comparable rates and are considered to be the major
enzyme candidates for metabolism of extracellular diadenosine
polyphosphates in vertebrate tissues [130]. NPP6–7 hydrolyse
only phosphodiester bonds in lysophospholipids or other cho-
line phosphodiesters, while natural substrates for NPP4–5 still
remain unknown. Notably, an unambiguous distinction between
the members of NPP and NTPDase families is often compli-
cated by their co-expression to a variable extent among the
mammalian tissues and shared similarities in substrate specificity
[21,109]. The contribution of these two nucleotidases could be
estimated by autoradiographic analysis of the relative amounts of
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However, it has to be kept in mind that, due to broad substrate
specificity, some NPP can also dephosphorylate ATP via ADP to
AMP in a “NTPDase-like” fashion.
The mammalian members of the NPP1–3 family are thought
to be a type II (intracellular N-terminus) transmembrane glyco-
proteins of 110 to 125 kDa that share a highly homologous
extracellular domain containing two somatomedin B-like do-
mains of vibronectin and a highly conserved catalytic site [23].
More recent data revealed that NPP2 is not a transmembrane
protein but is synthesized as a pre-pro-enzyme. Following the
removal of the N-terminal signal peptide and further trimming
by a furine-type protease, NPP2 is secreted [24]. NPP2 (auto-
taxin)-deficient mice die at embryonic day 9.5 with profound
vascular defects, while heterozygous mice appeared healthy but
showed half-normal NPP2 activity and low plasma level of
lysophosphatidic acid (LPA) [132]. These studies demonstrated
that NPP2/autotaxin primarily functions as a lysophospholi-
pase-D, converting lysophosphatidylcholine into the lipid me-
diator LPA and further underlined vital role of the autotaxin-
LPA axis in vascular development.
Human NPP1 is highly expressed in bone and cartilage, with
intermediate enzyme expression in heart, liver, placenta, kidney
and testis [23]. In bone tissue, NPP1 activity is mainly associated
with osteoblast- and chondrocyte-derived membrane structures
termed “matrix vesicles”, where it has been identified as the key
PPi-generating enzyme ensuring normal bone matrix miner-
alization and soft tissue calcification [133]. Mice lacking NPP1
spontaneously develop articular cartilage, perispinal and aortic
calcification at a young age [134]. These knockout animals share
similar phenotypic features with a human disease, idiopathic
infantile arterial calcification, where a deficiency in NPP1-me-
diated production of PPi has been postulated to cause arterial
calcification and periarticular calcifications of the large joints
[135]. Note, PPi has a dual physiological role: it can function
as a promoter of mineralization at low concentrations (0.01–
0.1 mmol/L), but also acts as an inhibitor of mineralization at
higher concentrations [133]. There is increasing evidence that
the extracellular concentration of PPi is maintained within a
narrow physiological range via the opposing and reciprocal
actions of NPP1, which generates PPi, and tissue-nonspecific
alkaline phosphatase (TNAP), which further degrades it to Pi
[28]. Indeed, data with double knockout mice revealed that
deletion of both NPP1 (Enpp1−/−) and TNAP (Akp2−/−) genes
leads to a less severe phenotype than single knockouts where
only one gene was deleted [136].
4.3. Ecto-5'-nucleotidase/CD73
To date, seven human 5'-nucleotidases have been isolated and
characterised, with five of the enzymes located in the cytosol,
one in the mitochondrial matrix and one attached to the outer
plasma membrane. The intracellular nucleotidases generally
dephosphorylate 5'-ribonucleoside monophosphates with low
affinity (KmN10
−3 M), share an ability to hydrolyse 5'-(deoxy)
NMPs and 2'- and 3'-NMPs as substrates and mainly participate
in salvage pathways and/or de novo nucleotide synthesis [26].Surface-associated ecto-5'-nucleotidase, otherwise known as
CD73, efficiently hydrolyses 5'-AMP with Km of 3–50 μM and
shows no activity towards nucleoside 2'- and 3'-monopho-
sphates [25,26]. The mammalian ecto-5'-nucleotidase consists
of two (glyco)protein subunits with apparent molecular masses
of 60–70 kDa, which are tethered by non-covalent bonds [137],
binds zinc and other divalent metal ions at the N-terminal
domain [138] and is anchored to the plasma membrane at the
C-terminus by glycosyl-phosphatidylinositol (GPI) [25,26].
This ectoenzyme belongs to a large superfamily of dinuclear
metallophosphoesterases acting on diverse substrates such as Ser/
Thr phosphoproteins, various nucleotides and sphingomyelin
[138].
Ecto-5'-nucleotidase is expressed to a variable extent in dif-
ferent tissues, with abundant expression in the colon, kidney,
brain, liver, heart and lung [25,37,139,140]. In the vasculature,
ecto-5'-nucleotidase is predominantly associatedwith the vascular
endothelium of large vessels such as the aorta, carotid and coro-
nary artery [59]. In the case of circulating T- and B-lymphocytes,
the enzyme expression is restricted by certain cell types and
strongly correlates with cell maturity, while neutrophils, erythro-
cytes, platelets and other blood cells express little or no CD73
[141–143]. Specifically, ecto-5'-nucleotidase/CD73 is co-
expressed with NTPDase1/CD39 on the surfaces of CD4+/
CD25+/Foxp3+ Treg cells and comprises an important constituent
of the suppressivemachinery via conversion ofATP/ADP-derived
AMP further into the anti-inflammatory mediator adenosine and
subsequent inhibition of T cell proliferation and secretion of
cytokines [108,144]. While the major physiological role of ecto-
5'-nucleotidase seems to be the regulation of purinergic signalling
cascade [27], other non-enzymatic functions of the CD73 mole-
cule have also been proposed, such as induction of intracellular
signalling and mediation of cell–cell and cell–matrix adhesions
[141,145].
A number of substances were shown to regulate ecto-5'-
nucleotidase expression in vascular endothelial cells and hema-
topoietic cells in a cell type-specific manner, including the
cytokine interferon-γ [146], PMA [147], inhibitor of HMG-CoA
reductase lovastatin [148], adenosine analogue 5'-(N-ethylcar-
boxoamido)adenosine (NECA) and other cAMP-activating
agents forskolin and prostaglandin-E2 [149]. In intestinal epi-
thelia, ecto-5'-nucleotidase is predominantly localized on the
apical cell surface [51] and its expression can be further up-
regulated by hypoxia-inducible factor-1α, leading to increased
extracellular adenosine formation that in turn, counteracts hy-
poxia-induced intestinal permeability and protects the epithelial
barrier [150]. Interestingly, the efficacy of the anti-inflammatory
drugs methothrexate and sulfasalazine in the treatment of rheu-
matoid arthritis has been well documented for a long time.
However, it was only recently reported that both compounds
could mediate their anti-rheumatic effects by a mechanism that
requires ecto-5'-nucleotidase-mediated conversion of adenine
nucleotides and subsequent activation of adenosine receptors
[151,152].
Recently, three separate groups have generated the mice with
a genetic deficiency of CD73. These mice have been particularly
characterised in the context of a role for ecto-5'-nucleotidase in
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[153,154], pulmonary integrity and lung function [127,155],
immunomodulatory and thromboregulatory responses [27,59,
60,139], and cardioprotection during myocardial ischemia [61].
Specifically, data with ecto-5'-nucleotidase/CD73−/− mice have
identified CD73-catalyzed production of adenosine as one of the
control points for maintenance of vascular barrier function in
various tissues during hypoxia [27,139]. CD73-mediated adeno-
sine formation was also shown to protect pulmonary integrity in
murine models of lung injury induced by the drug bleomycin
[155] or mechanical ventilation [127]. Studies from another
group who generated CD73-deficient mice found an increase in
neointimal plaque formation and macrophage accumulation in
CD73−/− mice after wire injury of carotid arteries and further
emphasized the importance of CD73 in finely tuned constitutive
regulation, balancing proinflammatory and anti-inflammatory
mechanisms in the vasculature [60].
4.4. Alkaline phosphatases (AP)
AP are ubiquitous enzymes present in many organisms from
bacteria to man. With few exceptions, AP are homodimeric
enzymes and each catalytic site contains three metal ions (two Zn
and one Mg), necessary for enzymatic activity [28,156]. Mam-
malian AP display broad substrate specificity towards different
phosphomonoesters and other phosphated compounds, includ-
ing adenine nucleotides, pyrophosphate, phosphatidates with
various fatty acid chains, inorganic polyphosphates, glucose-
phosphates, β-glycerophosphate, bis(p-nitrophenyl) phosphate,
with release of inorganic phosphate and with a pH optimum for
this catalytic reaction lying in the alkaline range from 8 to 11
[156,157]. Three isozymes are tissue-specific and 90–98% ho-
mologous, i.e. intestinal AP, placental AP and germ cell AP,
while the fourth isozyme, TNAP, is ~50% identical to the other
three isozymes and is abundantly expressed in bone, liver, kid-
ney and, at lower levels, in some other tissues [28].
A major role for TNAP in bone tissue is to hydrolyse PPi to
maintain a proper concentration of this mineralization inhibitor
ensuring normal bone mineralization [136,158]. The clearest
evidence that AP are important in vivo has been provided by
studies of human hypophosphatasia, which is associated with
poorly mineralized cartilage (rickets) and bones (osteomalacia)
and spontaneous bone fractures. The primary biochemical de-
fect in this condition is a deficiency of the TNAP isozyme
caused by missense mutations in the human ALPL (TNAP)
gene, which leads to greatly elevated levels of extracellular PPi
and increased urinary excretion of pyridoxal-5'-phosphate, PPi
and phosphoethanolamine [28]. Two TNAP-deficient mouse
models (Akp2−/−) have been developed independently [159,160],
and both strains of knockout animals were characterised by
marked bone and cartilage abnormalities that generally pheno-
copied the human disease known as infantile hypophosphatasia.
While the important regulatory role of bone TNAP during the
development and mineralization of the skeleton has been well
established, the functions of AP in other organs are less understood.
Given that one of the natural substrates of TNAP is pyridoxal-5'-
phosphate (a phosphated form of vitamin B6), it is possible that arole of liver TNAP is to participate in themetabolismof this vitamin
[28,156]. Intestinal AP isozyme is likely to be involved in the
intestinal absorption and detoxification of lipids via its association
with surfactant-like particles, while the placental AP might be
involved in mediating immunoglobulin-G transport through the
placenta and growth and remodelling of fetal tissues [28].
Experiments conducted on cultured human nasal epithelial cells
and freshly excised bronchial tissues indicated that TNAP could
also contribute, in conjunction with ecto-5'-nucleotidase, in the
regulation of adenosine-mediated epithelial functions [161]. Spe-
cifically, although ecto-5'-nucleotidase still remains more efficient
at producing adenosine from physiological AMP concentrations
(10−6–10−5 mol/L), the high-capacity TNAP can protect the
mucosal surface against the deleterious effects of acutely elevated
nucleotide levels, thus playing an important role in airway defences
during periods of infection and inflammation. Recent data on
selective expression of TNAP on certain subsets of progenitor cells
in the murine brain and modulation of its nucleotide-hydrolysing
activity during embryonic and postnatal development also suggests
the important role of this ectoenzyme in the regulation of purinergic
signalling and embryonic neurogenesis [111].
5. Ectoenzymatic inactivation of adenosine and other
nucleosides
5.1. Adenosine deaminase (ADA)
ADA is another important enzyme of the purine-inactivating
chain, which catalyzes the irreversible deamination of adenosine
and 2'-deoxyadenosine to inosine and 2'-deoxyinosine respec-
tively and is widely expressed in intestine, thymus, spleen and
other lymphoid and non-lymphoid tissues [32,140]. Along with
cytosolic localization, ADA can be expressed as an ectoenzyme
on the surfaces of lymphocytes [36,162] and dendritic cells
[163,164]. Interestingly, liver, monocytes/macrophages and
serum also contain another isozyme, ADA2, with a low substrate
affinity (Km for adenosine ~2 mM). ADA2 can be active at sites
of inflammation during hypoxia and in areas of tumor growth
and in addition, it binds to heparin and belongs to a new family of
ADA-related growth factors [165].
On lymphoid cells, extracellular ADA is often associated in
larger complexes with CD26/dipeptidyl peptidase IV [166,167] or
via alternative anchoring mechanism by interacting with A1 or A2b
adenosine receptors [163,168]. Recent radio-TLC assays with [3H]
adenosine as substrate confirmed cell-surface expression of cata-
lytically active ADA on human lymphocytes [30]. HPLC data
shown in Fig. 4A provide another line of evidence for the ability of
lymphocytes to directly deaminate exogenous adenosine, and
similar results have been reported recently in studies with mouse
bone marrow-derived dendritic cells [164]. Taking into account the
important anti-inflammatory role for adenosine, abundant expres-
sion of ecto-ADA in the lymphoid tissues may provide an efficient
means for scavenging cell-surrounding adenosine with subsequent
sustained activation of dendritic cells and T-lymphocytes during
inflammation, even despite the general state of immune suppression
[164]. In addition, lymphoid ecto-ADA, in association with CD26,
has been proposed to have a catalytic-independent function as a co-
Fig. 4. Metabolism of exogenous nucleosides by human lymphocytes. Human
leukemic T cells Jurkat were incubated with 50 μM adenosine (A) and inosine
(B) for 0–60 min. Exogenous nucleoside substrates and their metabolites were
separated by reverse-phase HPLC and are indicated in the chromatograms shown.
For experimental details, see [77,119].
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engagement [166], and during the immunological synapse
formation [163], thus promoting an augmented T cell activation
and production of proinflammatory cytokines. Compared with
lymphocytes, vascular endothelium displays relatively low ecto-
ADA activity [30], however endothelial cell-surface expressions
of ADA and its counter-ligand CD26 can be coordinately up-
regulated in areas of ongoing inflammation and diminished
oxygen supply [169].
ADA deficiency in humans arises from naturally occurring
mutations that account for approximately 20% of cases of human
severe combined immunodeficiency disease and affects both cell-
mediated and humoral immunity. Genetic deficiencies in ADA in
humans result in a severe lymphopenia and immunodeficiency and
in addition, exhibit phenotypes in other physiological systems
including the renal, neural, skeletal and pulmonary systems
[36,170]. ADA-deficient mice have been generated by two groups
with similar phenotypes noted [171,172]. The ADA-deficient
fetuses die perinatally, around 18.5 days post coitum, in association
with severe liver impairment and failure of lung expansion pre-
sumably due to marked accumulations of cytotoxic 2'-deoxyade-
nosine and adenosine. This prenatal lethality of ADA-deficient
fetuses was overcome by the ectopic expression of an ADA
minigene in the gastrointestinal tract of otherwise ADA-deficient
mice [173]. ADA-deficient mice develop a severe pulmonary
phenotype and combined immunodeficiency similar to that seen in
ADA-deficient humans, and experiments in these mice have
confirmed the key role of adenosine signalling in severe immu-
nodeficiency diseases, including chronic inflammatory lung
diseases [36]. Along with severe pulmonary insufficiency, ADA-
deficient mice also exhibited bone abnormalities and kidney path-
ogenesis [36,173]. Noteworthy, in spite of the obvious beneficial
effects of daily enzyme replacement (by injecting a polyethylene
glycol (PEG)-modified form of bovine ADA) in ADA-deficient
patients and ADA−/− mice, relatively high doses are required to
correct the phenotypic abnormalities [36], presumably reflectingthe inability of PEG-conjugatedADA to leave the circulation, enter
the cell or penetrate the blood-brain barrier.
5.2. Purine nucleoside phosphorylase (PNP)
PNP is the enzyme next to ADA in the purine catabolic
pathway that is mainly localized in cytoplasm of both prokaryotic
and eukaryotic organisms as a trimeric complex of ~90–100 kDa,
but can also be found in the mitochondria [140,174]. The major
role of mammalian cytosolic PNP is to phosphorylate (deoxy)
guanosine and (deoxy)inosine to guanine and hypoxanthine
respectively, which are then metabolised via xanthine to the stable
end-reaction product uric acid. Interestingly, incubation of human
nasal and bronchial epithelial cells [161] and leukemic cell lines
[83,88] with [3H]adenosine and subsequent chromatographic
imaging of the reaction products elicited significant conversion of
the generated [3H]inosine further to [3H]hypoxanthine. TheHPLC
chromatograms shown in Fig. 4B further confirm that lympho-
cytes are able of converting inosine to hypoxanthine, without
significant nucleoside uptake by the cells. Together, these data
suggest that PNP can also be expressed on the cell surface where it
regulates, in conjunction with ADA, local nucleoside levels.
Mutations that interfere with the production or function of PNP
in humans disturb intracellular nucleotide/nucleoside homeostasis
and result in severe T cell immunodeficiency, immune and neuro-
logical dysfunctions. These immune abnormalities in turn, con-
tribute to the early death of PNP-deficient patients in the childhood
from infections, autoimmunity or malignancy [175,176]. The
PNP−/− mice display metabolic, immune and phenotypic abnorm-
alities similar to those found in PNP-deficient patients, which are
particularly manifested in markedly reduced mitogenic and
allogenic responses, hypoplasmic thymi, decreased numbers of
maturing thymocytes and peripheral T cells, impaired thymocyte
differentiation and abnormal T lymphocyte responses [177].Recent
data on the ability of PNP fused to a protein transduction domain
(PTD–PNP) to normalize the abnormal function of PNP-deficient
lymphocytes in vitro [174] and to increase the survival of PNP−/−
mice in vivo [178] provide promise for the efficient delivery of PNP
into various tissues, including the brain, and preventing metabolic
disorders in purine homeostasis. Notably, while not as efficient as
PTD–PNP, non-fused PNPalso improved the viability and function
of PNP-deficient human lymphocytes [174], increased thymus
weight and corrected the immune disorder in PNP−/− mice [178].
While the authors explained the beneficial effects of this cell-
impermeable PNP by creating an extracellular purine concentration
gradient which could remove toxic metabolites from the cells, an
alternative interpretation for these findings, by ectoenzymatic
regulation of purinergic signalling via shifting the local nucleoside
levels is also possible.
6. ATP re-synthesis via backward ecto-phosphotransfer
reactions
6.1. Adenylate kinase (AK)
AK catalyzes reversible phosphoryl transfers ATP+AMP↔
2ADP through an associative path with a pentacoordinate
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with respect to phosphate acceptors NMP [78]. The enzyme
isoforms are thought to be mainly localized in the cytosol
(AK1), mitochondrial intermembrane space (AK2), mitochon-
drial matrix (AK3) and nucleus (AK6) where they play a critical
role in energy transfer and distribution between mitochondria,
cytosol and nucleus [78,179,180]. The cytosolic AK1 is con-
sidered one of the most prominent members of the AK family
and is expressed in well-differentiated tissues with a high-
energy demand, like brain, heart and skeletal muscle. In ad-
dition, a novel isoform of cytosolic enzyme, AK1β, was shown
to be localized in the plasma membranes of various tissues
[181,182]. This membrane AK1β differs from the cytoplasmic
AK1 by 18 extra amino acids at the N-terminus containing a
consensus signal for protein myristoylation and the fatty acid
chain enables its binding to the lipid bilayer [181]. By using
two-photon excitation fluorescence imaging, it has been shown
that AK1β undergoes lateral diffusion within the plasma mem-
brane, is continuously exchanged with cytosolic AK1 and is
likely interacting with other membrane proteins [183].
AK1 knockout muscles display lower energetic deficiency
and increased vulnerability to metabolic stress, associated with
a compromised ability to maintain adenine nucleotide pools and
inefficient signal communication to the nucleus and cytosolic
metabolic sensors [179,184]. Recent study also demonstrated
that along with defective myocardial energetic communication,
AK1 deficiency blunts AMP signal generation and adenosine
efflux in the vasculature and further abrogates coronary reflow
after ischemia–reperfusion [185]. AK-mediated phosphotrans-
fer also provides an efficient way to couple transport to the
cellular metabolic state and facilitates delivery of intracellular
signals to the membrane environment, which might occur via
association of cytosolic AK1 [186] and/or membrane-asso-
ciated AK1β [182] with the ATP-sensitive potassium (KATP)
channels. Interestingly, ABC transporter CFTR can also func-
tion either as an ATPase or as an AK, with the latter phos-
photransfer reaction being directly implicated in gating of this
anion channel in vivo [187,188]. Likewise, other member of
ABC family Rad50 that associates in a tight complex with an
exo-/endonuclease Mre11, also catalyze both ATP hydrolysis
and reversible AK reaction and in this way, plays an important
role in DNA double-strand break repair [189].
Recent identifications of ecto-AK activities on human vas-
cular endothelial cells [76], lymphocytes and leukemic cell lines
[30], hepatocytes and hepatic cell lines [46,190], airway epi-
thelia [75,191], keratinocytes [47], rat hippocampus [192] and
other cell types suggest a novel role for this enzyme in the
control of extracellular nucleotide levels and propagation of
purinergic signalling. Notwithstanding, only moderate ADP-to-
ATP conversion has been detected on the cultured HUVEC by
using colorimetric tetrazolium reduction assay, and on this basis
the authors concluded that external AK activity is “an artefact
primarily reflecting a minor leakage of intracellular enzyme
from living cells and/or a few dying cells” [193]. Such an
interpretation needs critical reassessment though as the revealed
phenomenon of little ATP formation from ADP simply reflects
the fact that endothelial NTPDase/ADPase exceeds ecto-AKactivity by ~5-times [76] and hence, a nucleotide-hydrolysing
pathway prevails under these experimental settings. In contrast,
joint addition of [3H]AMP and non-labelled ATP (which serves
as a donor of γ-phosphoryl groups and concurrently inhibits
ecto-5'-nucleotidase) to the HUVEC and subsequent TLC ana-
lysis of the generated high-energy 3H-phosphoryls ADP/ATP
provides a more reliable tool for measuring the (ecto)phos-
photransfer reactions [76]. Further comparative studies with
viable cells and their lysates unequivocally confirmed that a
significant portion of AK is indeed expressed as an ectoenzyme
on surface of endothelial cells [30].
6.2. NDP kinase
NDP kinase is a ubiquitous enzyme which catalyzes transfer
of γ-phosphate from nucleoside 5'-triphosphates to nucleoside
5'-diphosphates via a phosphoenzyme intermediate, requires
Mg2+ or other divalent cations, and has a broad substrate spe-
cificity towards different ribo- and deoxyribonucleotides of
purines and pyrimidines [194]. All NDP kinases are oligomeric
proteins made of 17–20-kDa subunits with highly conserved
sequences, which are thought to be mainly localized in the
mitochondria, cytosol and nucleus where they link ATP-based
energetics with the cellular NTP pool and facilitate channelling
of nucleoside triphosphates into protein synthesis and DNA
replication complexes [195,196]. Apart from its role in main-
taining the balanced levels of nucleoside triphosphates in the cell,
NDP kinase can have additional regulatory functions for growth
and developmental control, signal transduction and tumor meta-
stasis suppression [195–197]. Specifically, the nm23 tumor me-
tastasis suppressor gene was found to encode a protein identical
to NDP kinase and to date eight different genes (nm23-H1 to
nm23-H8) have been identified in humans [196]. Mice lacking
the Nm23-M1 gene (the murine homologue of Nm23-H1) have
been generated recently, and these knockout animals are charac-
terised by a high rate of neonatal mortality, the impaired mam-
mary gland development and growth retardation [198].
Although it has become obvious that NDP kinase is an im-
portant multifunctional protein, little is known about the mole-
cular mechanisms underlying its antimetastatic effects and role in
cell biology. Interestingly, NDP kinases/Nm23 was shown to
form stable complexes with a number of other cellular proteins,
including molecular chaperones of the Hsp70 family and cyto-
skeletal components vimentin and tubulin [195], several enzymes
involved in energy metabolism [179], AMP-activated protein
kinase [199] and serine–threonine kinase receptor-associated
protein [200]. Probably, some of these proteins could provide a
physical link between NDP kinase/Nm23, cellular bioenergetics
and transmembrane signalling cascades.
Renewed interest in this enzyme emerged from recent data
showing that NDP kinase participates in outside-in and inside-out
signalling either via recruitment onto the plasma membrane or
constitutive expression as a cell-surface ectoenzyme. Particularly
during cell migration or early stages of cell spreading, Nm23-H2
is recruited in the vicinity of integrins and co-localized with
the negative regulator of β1-integrin-mediated cell adhesion,
ICAP-1α, thereby interfering with the cell/extracellular matrix
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more, it has been shown that the effects of ADP-Rybosilation-
Factor-6 (ARF6), a member of the ARF family of proteins
functioning as a molecular switch by cycling between active
GTP-bound and inactive GDP-bound conformations, are depen-
dent on the recruitment ofNm23-H1 to cell–cell contactswhich in
turn, induces a decrease in the cellular levels of a small GTPase
protein Rac1 [202]. These studies provide a molecular basis for
dynamin-mediated endocytosis during adherens junction disas-
sembly in polarized epithelia. More recent studies further demon-
strated that Nm23-H1might regulate Rac1-induced cell migration
and focal adhesion functions via dynamic association with a
human prune (h-prune), which displays high cAMP-specific
phosphodiesterase activity and has additionally been identified as
a glycogen synthase kinase-3 binding protein [203].
The first evidence for extracellular ATP synthesis via the ecto-
NDP kinase reaction was provided over three decades ago in
experiments with human erythrocytes [204] and cultured glioma
and glia cell lines [205]. Since that time, cell-surface expression
of NDP kinase has been documented in various tissues, including
pig aortic endothelial and smooth-muscle cells [95], human
astrocytoma cells [29], vascular endothelial cells [76], lympho-
cytes [30], hepatocytes [46], keratinocytes [47], perfused guinea-
pig coronary arteries and cultured heart endothelial cells [44].
Interestingly, a role for spatially arranged near-equilibrium enzy-
matic networks (so-called “phosphoryl wires”), catalyzed by
intracellular AK, NDP kinase, creatine kinase and glycolytic
enzymes, in supporting high-energy phosphoryl transfer and
communication between ATP-generating and ATP-consuming/
ATP-sensing processes has emerged recently [179,180]. Data on
the cell-surface expression of nucleotide kinases, together with
the ability of the cells to retain substantial amounts of ATP in their
vicinity (see Section 3), allow one to expand the above concept
by hypothesizing the co-existence of spatially anchored intra-
and extracellular phosphotransfer networks coordinating ener-
getic homeostasis and metabolic signalling between cell com-
partments and along the interstitial space.
6.3. ATP synthase
ATP synthase (also called F1F0 ATP synthase) is the uni-
versal enzyme found in the bacterial cytoplasmic membrane, the
inner membrane of mitochondria and the thylakoid membrane
of chloroplasts where it transforms energy from a transmem-
brane electrochemical gradient of protons into the phosphoric
acid anhydride bond of ATP [206]. ATP synthase is a large
protein complex (~500 kDa) composed of a central membrane-
embedded portion (Fo) and a water-soluble “headpiece” com-
plex (F1). The complete complex harnesses the energy released
by proton-motive force (which is the sum of the pH gradient and
the membrane potential) to drive ATP synthesis and this process
of oxidative phosphorylation needs NADH or FADH2, oxygen,
ADP and inorganic phosphate. The F1 portion of ATP synthase
(known as F1-ATPase or H
+-ATPase) contains five types of
polypeptides in the ratio (αβ)3γδε and alone, without coupling
to electron transport, it behaves as a rotatory engine mediating
backward ATP hydrolysis via rotation of subunit γ relative to(αβ)3 [206,207]. Interestingly, the mammalian ATP synthase in
its native state was shown to be localized in a cristae-like sub-
fraction of the mitochondrial inner membrane, where it forms an
“ATP synthasome” supercomplex with two required transpor-
ters, the protein carrier and the adenine nucleotide carrier [208].
Although ATP synthase is generally believed to be expressed
in mitochondria, reports are accumulating that at least certain
components of this enzyme complex also exist on the outer face
of plasma membrane. Das et al. [209] first demonstrated the
expression of a 51.5-kDa protein on the plasma membrane of
several tumor cell lines, that has homology to the β-subunit of
mitochondrial H+-ATPase and is involved in an interaction with
cytotoxic lymphocytes. More recently, Moser et al. [210] re-
ported that both α- and β-subunits of ATP synthase co-localize
on the surface of cultured HUVEC and can be involved in the
regulation of angiogenesis via direct binding of angiostatin, a
potent antiangiogenic and antitumorigenic agent. Subsequent
studies confirmed the ectopic localization of ATP synthase com-
ponents on human vascular endothelial cells [211], adipocytes
[212], keratinocytes [47] and various tumor cell lines [213],
where they might participate in diverse processes such as regu-
lation of lipid metabolism, immune responses, tumor metastasis
and regression, as well as in control of cell proliferation and
differentiation. It has also been shown recently that an entity
related to the mitochondrial F1-ATPase is expressed on the tumor
cell surface where it binds a delipidated form of apolipoprotein
A-I, and promotes tumor recognition byVγ9Vδ2 Tcells, a major
γδ T lymphocyte subset in humans [214].
While most of the above studies have defined this ecto-ATP
synthase as a “catalytically active complex”, strictly speaking, no
direct evidence supporting this statement had been provided so
far. In fact, the assignment of cell-surface expression of ATP
synthase is primarily based on immunofluorescence and electron
microscopic observations, proteomic studies and structural and
biochemical analyses of plasma membrane fractions after bio-
tinylation of cell-surface proteins. As for the ability of this ecto-
protein to generate ATP from ADP and orthophosphate using
proton-motive force, this inference mainly rests on biolumine-
scent assays showing a significant increase in extracellular ATP
levels within the first minute after addition of micromolar ADP
concentrations, and on partial inhibition of this ADP→ATP
conversion by oligomycin and other inhibitors of ATP synthase.
However, such interpretation of data on extracellular ATP
synthesis needs critical reassessment. Firstly, we [30,76] and
others [46,47,193] also elicited ADP-to-ATP conversion on the
surface of various cell types. However, marked inhibition of this
reaction by a specific inhibitor of AK (diadenosine pentapho-
sphate, Ap5A) in these studies suggests the predominant contri-
bution of ecto-AK, rather thanATP synthase, to extracellular ATP
generation from ADP. Secondly, the abundant expression of yet
another nucleotide-phosphorylating ectoenzyme, NDP kinase,
does not exclude the possibility of immediate ADP transpho-
sphorylation with endogenous ATP and other non-adenine nu-
cleotides [44], which can be either acutely released upon
mechanical cell stimulation (during addition of exogenous
ADP) or constitutively retained in the cell vicinity at micromolar
levels (see Section 3). Thirdly, dual-label TLC assays with [3H]
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3H]ATP generated
from [3H]ADP on surface of human hepatocytes was not 32P-
labelled and thus, this catalytic reaction did not require 32Pi for
ATP synthesis [46]. The inability of millimolar concentrations of
non-labelled inorganic phosphate to increase the rate of [3H]ADP
conversion into [3H]ATP was also confirmed in studies with
human endothelial cells [76] and hepatocytes [46]. Lastly, the
specificity of the inhibitors used to discriminate between the F1/
F1F0 contributions has not been tested on other purinergic ecto-
enzymes, which also might lead to misleading interpretation of
the results. Collectively, while certain components of ATP syn-
thase can be expressed on the cell surface and serve as receptor for
angiostatin and othermultiple ligands, further studies are required
to elucidate the contribution of this ectoprotein into purinergic
signalling via extracellular ATP synthesis.
7. Coordinated control of purinergic signalling via a network
of purinergic ectoenzymes
7.1. Interplay between ATP-consuming and ATP-regenerating
pathways
Current findings support the presence of an extensive net-
work of ectoenzymes that are co-expressed to a variable extent
among the mammalian tissues and share similarities in substrate
specificity. In principle, the duration and magnitude of puri-
nergic signalling can be coordinated via two opposite, ATP-
consuming and ATP-regenerating, pathways, where sequential
nucleotide breakdown to adenosine and further to inosine/
hypoxanthine is counterbalanced by re-synthesis of high-energy
phosphoryls through backward phosphotransfer reactions [30].
Under normal physiological conditions, the ecto-nucleotide ki-
nase activities seem not to compete with ecto-nucleotidases for
a limited pool of the released nucleotide substrate. Indeed, the
nucleotide-binding centres of AK are assembled with large
domain movements upon simultaneous binding of both sub-
strates, whereas the existence of enzyme either in ATP- or
AMP-bound forms does not cause sufficient conformational
changes [78]. Therefore, the release of a particular nucleotide
alone would cause its rapid inactivation through sequential ecto-Fig. 5. Ectoenzymatic purine turnover in the vasculature. The elements of purine-in
deaminase (ADA), and purine nucleoside phosphorylase (PNP), whereas an opposite
nucleoside diphosphate kinase (NDPK) reactions. Thin dashed arrows and vertical bnucleotidase reactions (Fig. 2). However, in the settings of in-
flammation or traumatic shock, extracellular levels of nucleotides
can be simultaneously increased up to 10−5–10−4 mol/L there-
by causing additive conformational changes of ecto-nucleotide
kinases. Acute changes in the specific ratios of nucleoside
mono-, di- and triphosphates, in conjunction with feed-forward
inhibition of ecto-5'-nucleotidase activity by precursor ATP/
ADP [76,96,215], should determine the directional shift from a
nucleotide-inactivating pathway towards backward ATP regen-
eration (Fig. 5).
7.2. Peculiarities of purine metabolism in the vasculature at
various (patho)physiological states
As stated above (see Section 4), specific ecto-nucleotidase
activities can be spatially compartmentalized within different
elements of the vasculature and also substantially vary among
different subsets of lymphoid cells. In this scenario, the cells
with high NTPDase and ecto-5'-nucleotidase activities, such as
vascular endothelium, tend to rapidly inactivate the released
ATP/ADP with respective generation of adenosine and in this
way, represent the major effector system for termination of
proinflammatory and prothrombotic responses in the cardiovas-
cular system [12,22]. In contrast, the combination of relatively
low ecto-nucleotidase and high ADA activities in the leukocytes
and other hematopoietic cells would allow cells of the immune
system either to generate less adenosine or to remove it more
efficiently from the environment and consequently protect cells
from its inhibitory effects [10,30]. Despite this general trend, the
NTPDase1/CD39 and ecto-5'-nucleotidase/CD73 activities can
be selectively up-regulated on a certain population of activated
CD4+/CD25+/Foxp3+ Treg cells, thereby contributing to the
maintenance of peripheral tolerance and control of the inflam-
matory autoimmune diseases [108,123]. These differences in
purine catabolism among the endothelial and lymphoid cells
might be particularly pertinent firstly, in the context of clear-cut
distinctions in the purinergic signalling pathways between these
cell types, and secondly, because of divergent, often opposite,
effects of ATP and its intermediate metabolite adenosine on
endothelial function and hemostasis [10,11].activating chain include E-NTPDases, ecto-5'-nucleotidase (5-NT), adenosine
ATP-regenerating pathway is mediated via sequential adenylate kinase (AK) and
lunted line depict activatory and inhibitory mechanisms, respectively.
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directionally modulated under certain physiological circum-
stances. For instance, in the promyelocytic HL60 cells, induced
to differentiate along the macrophage lineage by phorbol esters,
there were coordinated alterations in purinergic activities, ac-
companied by a switch from the adenosine-metabolising pheno-
type in undifferentiated cells toward the adenosine-producing
phenotype in macrophages [32,147]. Coordinate regulation of
purinergic activities occurring during cancer progression also
allows solid tumors to escape cytostatic effects of ATP and at
the same time, to maintain high concentrations of immunosup-
pressive and tumor-promoting adenosine [32].
Likewise, endothelial nucleotide-inactivating ectoenzymes
NTPDase1/CD39 and ecto-5'-nucleotidase/CD73 can be up-
regulated during acute hypoxia and inflammation and in this
way, increase the intravascular adenosine concentrations and
dampen excessive inflammatory responses by affecting endo-
thelial barrier function, adhesion and transmigration of lym-
phoid cells and expression of other molecules involved in the
adhesion cascade [52,169,216]. On the other hand, other inves-
tigators have shown significant down-regulation of ecto-nucleo-
tidase activities on vascular endothelium and other cell types
during chronic hypoxia and oxidative stress, that was accom-
panied by concomitant perturbation of nucleotide-mediated
signalling pathways and development of vascular disorders
[45,105]. Along with increased adenosine production, adaptive
responses to acute hypoxia might also include the diminished
adenosine uptake into the cell via concurrent decreases in the
expression levels of equilibrative nucleoside transporters [35],
as well as increased adenosine signalling caused by transcrip-
tional induction at the receptor level [48,139,150].
While most of the current studies have focused on the
concerted actions of ecto-nucleotidase activities, recent findings
on the co-expression of counteracting ATP-regenerating ecto-
enzymes suggest that regulation of purine metabolism might
extend beyond the inactivating pathways. Specifically, along
with low ecto-nucleotidase and high ADA activities, the lym-
phoid cells are characterised by relatively high ecto-AK and
NDP kinase activities [30] and in addition, are capable of
maintaining micromolar “ATP halo” in their immediate vicinityFig. 6. Regulation of purine metabolism during leukocyte-endothelial adhesion. Unde
and ADP via AMP to adenosine through sequential NTPDase and ecto-5'-nucleotid
relatively low ecto-nucleotidase activities, the lymphocytes are generally characterise
the adherent lymphoid cells (blue) could facilitate their transendothelial migration vi
remaining adenosine and (3) maintenance of external levels of proinflammatory AT[81,83]. This “ATP-regenerating/adenosine-eliminating” phe-
notype of lymphoid cells, in conjunction with leukocyte-gov-
erned suppression of endothelial ecto-5'-nucleotidase [11,88],
could represent a novel form of cross-talk between adherent
leukocytes and targeted endothelium which facilitates leukocyte
transmigration from the blood into the tissues (Fig. 6).
7.3. Membrane compartmentalization of ectoenzymes and other
components of purinergic signalling cascade
Based on kinetic analysis of sequential nucleotide break-
down by vascular endothelial and smooth muscle cells attached
to polystyrene beads, the “two-compartment” model has been
proposed earlier [96,215]. According to this model, extra-
cellular ATP and other nucleotide substrates are initially con-
centrated from the bulk phase on the cell surface followed by
preferential “hand-to-hand” delivery of the generated product
for the succeeding phosphatase reactions. This work nicely
foreshadowed the ensuing observations which directly demon-
strated the accumulation of relatively high ATP concentrations
in the cell vicinity (see Section 3). Another important discovery
from these kinetic studies of Slakey and colleagues is that the
nucleotide-inactivating ectoenzymes are located in close pro-
ximity with each other, presumably within certain caveolae or
pits. Membrane compartmentalization is an important feature
which permits divergent cellular functions to take place at
specific microdomains on the cell surface. These membrane-
specialized assemblies are formed by high concentrations of
cholesterol and sphingolipids immersed in a more fluid unsa-
turated glycerophospholipid environment, are enriched in GPI-
anchored proteins, caveolin and numerous signalling proteins,
and have been implicated in many cellular functions such as
signal transduction, endocytosis and cholesterol transport [217].
Like other GPI-anchored proteins, the enzyme ecto-5'-
nucleotidase/CD73 is mainly localized in these microdomains
[25,141], remains relatively resistant to the solubilization by
non-ionic detergents and can be cleaved from the cell membrane
after treatment with phosphatidylinositol-specific phospholi-
pase C [51,88,145]. Detailed localization studies based on
enzymatic assays and immunochemistry have shown that ther basal conditions, vascular endothelium efficiently inactivates extracellular ATP
ase reactions. In contrast, due to the high ecto-nucleotide kinase and ADA and
d by ATP-regenerating/adenosine-eliminating phenotype. During inflammation,
a (1) inhibition of endothelial ecto-5'-nucleotidase, (2) rapid deamination of the
P at relatively high levels.
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racteristic flask-shaped invaginations of the endothelial plasma
membrane, called caveolae [218]. Post-translational modifica-
tion (e.g. palmitoylation or phosphorylation) which is known to
influence association of proteins with rafts, can account for the
dynamic association of CD39 with lipid assemblies [219]. Cho-
lesterol depletion from human placental membranes by methyl-
β-cyclodextrin or cholesterol sequestration within the mem-
brane by filipin or nystatin treatments was also shown to affect
the conformation of the catalytic ecto-domain and strongly
inhibit both the catalytic and antiplatelet activities of CD39
[220]. Other components of the purinergic signalling cascade
could also be associated with lipid rafts and caveolae, including
ATP permeation sites [91], releasable ATP stores [83], ATP
synthase [211,212], adenosine A1 receptors [221] and nucleo-
tide-selective P2Y [222], P2X1 [223] and P2X3 [224] receptors.
8. Regulation of local nucleotide and nucleoside levels by
soluble enzymes
8.1. Soluble purine-inactivating and -phosphorylating activities
circulate in blood plasma
The ability of human plasma to dephosphorylate micromolar
concentrations of ATP and other adenine nucleotides into ade-
nosine and further to inosine/hypoxanthinewas first demonstrated
over half century ago [225]. Subsequent radio-TLC and HPLC
assays allowed the identification and kinetic characterisation of
at least three soluble nucleotidase activities in the human blood,
i.e. soluble ATPase, ADPase and AMPase (5'-nucleotidase)
[226,227]. More recent chromatographic analyses of the pattern
of [γ-32P]ATP breakdown by serum or plasma from humans and
other species (sheep, mouse, rabbit) revealed that circulating
ATP is primarily converted into AMP and PPi via soluble NPP
activity [77,228]. While the initial step of ATP breakdown in
human plasma is mainly attributable to NPP activity, recent
studies elicited the co-existence of another soluble enzyme
NTPDase which accounts for ~7–10% of the total soluble ATP-
hydrolysing pool and in addition, efficiently utilises ADP as
another preferred substrate [131]. Notably, additional ultracen-
trifugation of serum samples did not affect their nucleotide-
hydrolysing capacity [77,131], indicating that both NPP and
NTPDase presumably circulate in the human blood as “true”
soluble enzymes. The resulting AMP is then degraded via ade-
nosine to inosine through sequential 5'-nucleotidase and ADA
reactions, which are also present in the bloodstream as soluble
enzymes [77,122,227]. Furthermore, the co-existence of coun-
teracting nucleotide-phosphorylating pathway has been demon-
strated in human serum, with the elements of ATP-regenerating
chain comprising two soluble enzymes, AK and NDP kinase
[77,131]. Interestingly, the existence of soluble AK activity in
human plasma and its contribution to intravascular ADP meta-
bolism has been proposed four decades ago [229]. TNAP can
also be found in serum in an anchor-depleted form, where it most
likely regulates the intravascular PPi pool, while the contribution
of this phosphatase to the metabolism of circulating ATP seems
to be quite negligible [28].8.2. Physiological relevance of soluble versus
membrane-associated ectoenzymes
Understanding the physiological role of soluble enzymes
within the larger framework of membrane-associated ectoen-
zymes is another important issue. Under basal conditions, vas-
cular endothelial NTPDase1/CD39, in concert with ecto-5'-
nucleotidase/CD73, efficiently regulate nucleotide homeostasis
in the vasculature [12,105]. Among cellular elements of the
blood, the leukocytes, but not erythrocytes and platelets, also
contribute to the catabolism of circulating nucleotides, whereas
the activities of soluble nucleotidases in plasma are far less than
that on vascular endothelial and lymphoid cells [122,227].
However, vascular NTPDase activity can be diminished under
conditions of inflammation, thereby causing profound shifts in
vascular permeability and local procoagulant responses. The
strategies to offset the reduced nucleotide-scavenging effec-
tiveness of vascular endothelium include either NTPDase ex-
pression in the injured vessels or administration of soluble
nucleotidases for antiplatelet therapy [105]. Indeed, soluble
form of human NTPDase/CD39 is currently considered a pro-
mising aspirin-insensitive antithrombotic drug, which inhibits
platelet reactivity under experimental prothrombotic conditions,
including ischemia–reperfusion murine models of cerebral
shock [124], cardiac [129], hepatic [105], pulmonary [127] and
renal [128] injuries as well as various acute and chronic models
of transplantation [105]. Likewise, treatment with soluble 5'-
nucleotidase reduced infarct size and improved cardioprotection
both in wild-type and CD73−/− mice during acute myocardial
ischemia [61] and also attenuated tissue damage and improved
survival during acute lung injury [127].
Taken together, the above data suggest that soluble nucleo-
tidases could represent an important auxiliary effector system
for local inactivation of acutely elevated nucleotides, especially
at sites of injury and inflammation. Moreover, the identification
of soluble AK and NDP kinase capable of rapidly transpho-
sphorylating micromolar concentrations of nucleoside mono-,
di- and triphosphates [77] might represent a novel and currently
unappreciated route regulating the pattern of nucleotide receptor
stimulation and/or desensitization in the blood. Further studies
are required to understand the pertinence of soluble purinergic
activities within the larger framework of membrane-bound
ectoenzymes as well as to elucidate the origin and exact
mechanisms underlying their appearance in the bloodstream at
various (patho)physiological conditions.
8.3. Secreted Ca2+-activated nucleotidases and other purinergic
enzymes in other biological systems
The phenomenon of secreted purinergic enzymes has also
been documented in other biological systems. Specifically, a
certain portion of nucleotide-inactivating enzymes NTPDase
and/or 5'-nucleotidase can be released from the nerve terminals
of the guinea-pig vas deferens during electric stimulation [230],
human lymphocytes during mAb triggering [145], cultured
human endothelial cells in response to the application of shear
force [43], nasal lavage after stimulation of submucosal gland
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[231] and upon stimulation with cholecystokinin octapeptide-8
[106,119]. Exact cellular mechanisms underlying the releases of
soluble enzymes remain largely unclear and might particularly
involve selective shedding of ecto-5'-nucleotidase from the cell
surface via directional cleavage of its GPI-anchor [43,145] or
the presence of certain secretory pathways as it was suggested
for microvesicle-wrapped ATP-diphosphohydrolase/CD39
[106,231]. In a variety of human tumor cell lines, the consti-
tutive secretion of Nm23/NDP kinase protein can also be de-
tected [197]. In addition, significant release of catalytically active
AK and NDP kinase has been reported from human airway
epithelial cells and nasal lavage after stimulating submucosal
gland secretion [75].
Interestingly, the saliva of most blood-feeding arthropods
(including fleas, ticks, biting midges, and mosquitoes) also
contains potent soluble apyrases, designed to counteract a host's
normal blood-clotting mechanisms. Secreted by the arthropod
into the host's wound during blood-feeding, these soluble
apyrases inhibit hemostasis via rapid hydrolysis of intravascular
ADP into AMP and are strongly activated by Ca2+ [232]. Al-
though analogous to the E-type NTPDases with regard to their
enzymatic properties, these secreted enzymes from blood-
sucking insects are not homologous to the apyrase family with
regard to their amino acid sequences, contain invariant “nucleo-
tidase conserved regions” [233] and in addition, have related
homologs in humans, rodents and several invertebrates [234].
Recently, human [232] and rat [235] soluble Ca2+-dependent
apyrases related to two secreted apyrases of the bloodsucking
insects,Cimex lectularius and Phlebotomus papatasi, have been
cloned and characterised. However, in striking contrast to insect
subfamily members, these mammalian apyrases preferred GDP
and UDP as substrates. Using a combined structural biology
approach, Dai et al. were able to redesign human apyrase and
shifted its substrate specificity for ADP by more than 100-fold
[236]. This engineered enzyme potently inhibited ADP-induced
platelet aggregation and may serve as the basis for development
of a new class of antithrombotic agents for treatment of patients
with heart and vascular diseases.
9. Concluding remarks
Extracellular nucleotides and adenosine are versatile signal-
lingmolecules known to be implicated in an array of cell-specific
responses both in an autocrine and paracrine fashions. The inte-
gral response of the cell is determined by multiple factors,
including the release of endogenous ATP and other agonists,
expression of different types of receptors with respective diver-
sities in the transduction pathways, as well as specific make-up of
enzymes finely governing the duration and magnitude of puri-
nergic signalling. The data that have been described in this
review highlight the importance of nucleotide-releasing and
inactivating mechanisms in the regulation of cell responses and
on this basis provide a sufficient justification for re-examination
of the current concepts of purinergic signalling cascade.
In particular, nanomolar ATP concentrations detected in bulk
extracellular fluids by using conventional bioluminescent assaysare generally far below the micromolar (or even submillimolar)
EC50 values for most P2 receptors. This apparent discrepancy
could be reasonably resolved based on the innovative nucleo-
tide-sensing approaches providing independent lines of evi-
dence that the released ATP can be spatially confined in the
pericellular space at high micromolar levels with only minor
nucleotide portion being diffused and/or convected into the bulk
medium. Recent data on the ability of various cells to release,
along with ATP and ADP, other related compounds (adenosine,
UTP, dinucleoside polyphosphates and nucleotide sugars) gain
another important insight into our understanding of mechanisms
initiating a signalling cascade.
Next, the co-existence of two opposite, purine-inactivating and
ATP-regenerating, ectoenzymatic pathways represent a princi-
pally distinct route for appearance and inactivation of extra-
cellular agonists on the cell surface, where sequential ATP and
ADP breakdown to adenosine and further to inosine/hypoxan-
thine is counterbalanced by rapid interconversion of adenine
and non-adenine nucleotides via ecto-phosphotransfer reactions
(Fig. 5). The identification of a complex mixture of soluble
enzymes freely circulating in the bloodstream adds another level
of complexity to our understanding the regulatory mechanisms of
purine homeostasis in the vasculature and in addition, may open
up further research to assess the potential therapeutic and diag-
nostic applications of purinergic enzymes. Clearly, identifying the
exact mechanisms by which the extensive network of membrane-
associated and soluble enzymes regulates local nucleotide and
nucleoside concentrations and co-ordinately governs the pur-
inergic responses will be an area of intense interest in the future.
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